IPO registrations (S-1, F-1) · Registrants

Biohaven Pharmaceutical Holding Co Ltd.

SEC CIK
1689813 · filings on EDGAR ↗
Registration
Form S-1, first filed 2017-04-07, last 2018-12-10; 4 initial registrations, 2 amendments
Outcome
Final prospectus filed 2017-05-05; declared effective 2017-05-03
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
D8
Business address
215 CHURCH STREET, New Haven, CT 06510
EDGAR entity type
operating
Insiders and CEO pay
Biohaven Pharmaceutical Holding Co Ltd. on the corporate pages

Offering terms

Final price
$17.00 per share (424B4 filed 2017-05-05, an initial public offering)
Shares sold
9,900,000
Gross proceeds
$168,300,000 before underwriting discounts and any over-allotment option
Listing
NYSE under the symbol BHVN
Lead underwriters
Morgan Stanley; Piper Sandler (2,772,000 shares)
Syndicate
Barclays (1,485,000); William Blair (1,188,000); Needham & Company (495,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 14

FiledFormWhat it isName as filedEDGAR
2017-04-07S-1S-1 (registration)Biohaven Pharmaceutical Holding Co Ltd.0001047469-17-002426 ↗
2017-04-24S-1/AS-1/A (amendment)Biohaven Pharmaceutical Holding Co Ltd.0001047469-17-002826 ↗
2017-05-01S-1/AS-1/A (amendment)Biohaven Pharmaceutical Holding Co Ltd.0001047469-17-003101 ↗
2017-05-03S-1MEFS-1MEF (added securities)Biohaven Pharmaceutical Holding Co Ltd.0001104659-17-029582 ↗
2017-05-03EFFECTEFFECT (declared effective)Biohaven Pharmaceutical Holding Co Ltd.9999999995-17-001174 ↗
2017-05-05424B4424B4 (final prospectus)Biohaven Pharmaceutical Holding Co Ltd.0001047469-17-003184 ↗
2018-04-03S-1S-1 (registration)Biohaven Pharmaceutical Holding Co Ltd.0001047469-18-002486 ↗
2018-04-05EFFECTEFFECT (declared effective)Biohaven Pharmaceutical Holding Co Ltd.9999999995-18-000767 ↗
2018-10-02S-1S-1 (registration)Biohaven Pharmaceutical Holding Co Ltd.0001689813-18-000023 ↗
2018-10-17EFFECTEFFECT (declared effective)Biohaven Pharmaceutical Holding Co Ltd.9999999995-18-002648 ↗
2018-12-10S-1S-1 (registration)Biohaven Pharmaceutical Holding Co Ltd.0001628280-18-014980 ↗
2018-12-12S-1MEFS-1MEF (added securities)Biohaven Pharmaceutical Holding Co Ltd.0001628280-18-015071 ↗
2018-12-12EFFECTEFFECT (declared effective)Biohaven Pharmaceutical Holding Co Ltd.9999999995-18-003115 ↗
2018-12-14424B4424B4 (final prospectus)Biohaven Pharmaceutical Holding Co Ltd.0001628280-18-015109 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2017-05-01S-1/Aregistration statement$0.615,752,000$3,508,7200primary document; price line, shares headline, proceeds computeddocument ↗
2017-05-05424B4final prospectus$17.009,900,000$168,300,000NYSE BHVN5primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 5document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
AGUIAR ERICDirector152017–2020
Bailey GregoryDirector262017–2022
Berman RobertOfficerChief Medical Officer; Special Projects & Med Ovrsght232017–2020
Cha AlbertDirector42017–2018
CHILDS JOHN WDirector; Director,TenPercentOwner202017–2022
Conway CharlesOfficerChief Scientific Officer152017–2022
Coric VladDirector,OfficerChief Executive Officer192017–2022
Doogan DeclanDirector232017–2022
Engelhart JamesOfficerChief Financial Officer; Strategic Advisor212017–2022
Gentile KimberlyOfficerSVP, Clinical Operations; VP of Operations242017–2022
PORTAGE BIOTECH INC.Other; TenPercentOwner72017–2018
Tilton JohnOfficerCCO-Rare & Neurologic Disorder; Chief Commercial Officer162017–2022
GREGORY JULIA PDirector122017–2022
Repella RobertDirector32018–2019
JONES WILLIAM A JROfficerCCO-Migraine & Common Disease102019–2022
Stock ElyseOfficerChief Medical Officer152019–2022
Heffernan Michael ThomasDirector82020–2022
HUGIN ROBERT JDirector82020–2022
Mehta KishanDirector52021–2022
Clark George C.OfficerVP, Chief Accounting Officer82021–2022
Buten MatthewOfficerChief Financial Officer; Officer52021–2022
Antonijevic IrinaDirector32022

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2016-11-10Biohaven Pharmaceutical Holding Co Ltd.Pharmaceuticals$80,000,000$40,000,127341

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Form D issuerBiohaven Pharmaceutical Holding Co Ltd.CTForm D private offeringsCIK (EXACT)
IPO registrantBiohaven Ltd.CTIPO registrations (S-1, F-1)same street address and ZIP code, 215 CHURCH ST 06510 (FUZZY: a shared address, not proof of a shared organization)
Patent assigneeBiohaven Pharmaceutical Holding Company Ltd.CTPatents (USPTO)name and state
SEC filerBiohaven Pharmaceutical Holding Co Ltd.SEC filers (EDGAR)CIK (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, CT first:

More with this interest.

In other datasets, the same topic (Health) in CT:

Interests: Pharmaceutical Preparations · Health